As Chief Executive Officer, Mr. O’Brien is responsible for setting the strategy and delivering on the full financial potential of Genomind.
Prior to Genomind, O’Brien founded and served as chair of Key BioPharma Partners, LLC, a private biopharma consulting firm. He also served as president and CEO of Cipher Pharmaceuticals Inc., AltheRx Pharmaceuticals Inc., Profectus BioSciences Inc. and Solstice NeuroSciences Inc., in addition to his multiple senior global leadership roles within AstraZeneca.
O’Brien is board chair for Alto Pharma, a privately held company, and serves on the advisory boards of Greater Philadelphia Life Sciences Congress, and the Hubert J.P. Schoemaker Classic.
Bachelor’s degree in microbiology from University of Western Ontario, Manager & Leadership Certificate from the American Management Association. Graduate of the Marketing Leadership Programme at the Chartered Institute of Marketing, UK.